Literature DB >> 28012019

Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa.

G Rodari1, S Guez2, F Manzoni2, K K Chalouhi3, E Profka1, S Bergamaschi1, S Salera2, G Tadini2, F M Ulivieri4, A Spada1, C Giavoli5, S Esposito2.   

Abstract

Bone status impairment represents a complication of generalized forms of epidermolysis bullosa (EB); however, the prevalence and the main determinants of this event in localized forms remain poorly defined. Birmingham epidermolysis bullosa severity (BEBS) score and 25-hydroxyvitamin D levels are strongly associated with low bone mass, suggesting that vitamin D may play a potential beneficial role in bone health. Further longitudinal studies are needed in order to confirm this hypothesis.
INTRODUCTION: Bone status impairment represents a complication of generalized forms of EB; thus, we aimed to estimate the prevalence of low bone mass, to examine mineralization differences in various EB subtypes and to identify the most important determinants of bone impairment in children with either generalized or localized EB.
METHODS: An observational study of 20 children (11 males; mean age ± standard deviation, 11.7 ± 3.9 years) with EB was performed. Clinical history, physical examination, laboratory studies, X-ray of the left hand and wrist for bone age, and dual energy X-ray absorptiometry scans of the lumbar spine were obtained. Areal bone mineral density (aBMD Z-scores) and bone mineral apparent density were related to the BEBS score.
RESULTS: Areal BMD Z-score (mean -1.82 ± 2.33, range, -7.6-1.7) was reduced (<-2 SD) in 8 patients (40%), whereas aBMD Z-score adjusted for bone age was low in 7 patients (35%). BEBS score and 25-hydroxyvitamin D serum levels were the most important elements associated with aBMD (P = 0.0001 and P = 0.016, respectively). A significant correlation between the aBMD Z-score and area of skin damage, insulin-like growth factor-1, C-reactive protein, and sodium serum levels was also found.
CONCLUSIONS: Low aBMD can be considered a systemic complication of EB, primarily associated with BEBS score and 25-hydroxyvitamin D levels. Therefore, longitudinal evaluation of bone status is ongoing in these patients to define whether vitamin D supplementation would prevent, or at least reduce, bone status impairment.

Entities:  

Keywords:  BEBS score; Bone mineral density; Epidermolysis bullosa; Osteoporosis; Pediatrics; Vitamin D

Mesh:

Substances:

Year:  2016        PMID: 28012019     DOI: 10.1007/s00198-016-3883-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  30 in total

Review 1.  Acquisition of optimal bone mass in childhood and adolescence.

Authors:  L K Bachrach
Journal:  Trends Endocrinol Metab       Date:  2001 Jan-Feb       Impact factor: 12.015

2.  Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2012-03-22       Impact factor: 5.958

Review 3.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

Review 4.  Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.

Authors:  Jo-David Fine; Jemima E Mellerio
Journal:  J Am Acad Dermatol       Date:  2009-09       Impact factor: 11.527

5.  Vitamin D status and predictors of hypovitaminosis D in Italian children and adolescents: a cross-sectional study.

Authors:  Francesco Vierucci; Marta Del Pistoia; Margherita Fanos; Martina Gori; Giorgia Carlone; Paola Erba; Gabriele Massimetti; Giovanni Federico; Giuseppe Saggese
Journal:  Eur J Pediatr       Date:  2013-12       Impact factor: 3.183

6.  Correlates of low bone mass in children with generalized forms of epidermolysis bullosa.

Authors:  Anna L Bruckner; Laleh A Bedocs; Elizabeth Keiser; Jean Y Tang; Catherine Doernbrack; H Alan Arbuckle; Stephen Berman; Kyla Kent; Laura K Bachrach
Journal:  J Am Acad Dermatol       Date:  2011-05-07       Impact factor: 11.527

Review 7.  Osteoporosis in children and adolescents.

Authors:  Maria Luisa Bianchi
Journal:  Bone       Date:  2007-07-18       Impact factor: 4.398

8.  Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children.

Authors:  Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf
Journal:  J Clin Endocrinol Metab       Date:  2010-01-26       Impact factor: 5.958

9.  Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study.

Authors:  Angelo Valerio Marzano; Valentina Trevisan; Elisa Cairoli; Cristina Eller-Vainicher; Valentina Morelli; Anna Spada; Carlo Crosti; Iacopo Chiodini
Journal:  Orphanet J Rare Dis       Date:  2015-02-03       Impact factor: 4.123

10.  Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa.

Authors:  Giuseppina Annicchiarico; Maria Grazia Morgese; Susanna Esposito; Giuseppe Lopalco; Michele Lattarulo; Marilina Tampoia; Domenico Bonamonte; Luigia Brunetti; Antonio Vitale; Giovanni Lapadula; Luca Cantarini; Florenzo Iannone
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more
  2 in total

1.  Epidermolysis Bullosa in children: the central role of the pediatrician.

Authors:  Maria Rosaria Marchili; Giulia Spina; Marco Roversi; Cristina Mascolo; Elisabetta Pentimalli; Marialuisa Corbeddu; Andrea Diociaiuti; Maya El Hachem; Alberto Villani
Journal:  Orphanet J Rare Dis       Date:  2022-04-04       Impact factor: 4.123

2.  A single-centre study on predictors and determinants of pubertal delay and growth impairment in Epidermolysis Bullosa.

Authors:  Giulia Rodari; Sophie Guez; Simona Salera; Fabio Massimo Ulivieri; Gianluca Tadini; Michela Brena; Eriselda Profka; Federico Giacchetti; Maura Arosio; Claudia Giavoli
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.